Movement Alert｜Veradermics, Inc. Intraday Rise 8.14% in Regular Trading, prior clinical progress and cash runway remain in focus

Market Focus10-19

On October 19, Veradermics, Inc. rose 8.14% in Regular Trading, trading at $119.375 per share, with turnover of $31.8116 million.

The latest publicly available company-specific backdrop centers on earlier clinical and financial updates rather than a fresh same-day catalyst. The company previously reported second-quarter EPS of $(0.58), better than the $(0.65) consensus estimate, while net loss widened to $23.5 million from $15.6 million a year earlier but still came in below the expected $26.8 million loss. Veradermics, Inc. also said it held $819.9 million in cash, cash equivalents and marketable securities as of June 30, which it expects will fund operations into 2030 through multiple Phase 3 readouts and a potential commercial launch of VDPHL01.

Earlier pipeline updates showed VDPHL01 met all primary and key secondary endpoints in a Phase 2/3 male pattern hair loss trial, while a Phase 2 study in female pattern hair loss showed most participants reported improvement after six months with a favorable safety profile. Those developments remain central to how the market is assessing the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130777913?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-19 21:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130777913","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Veradermics, Inc. Intraday Rise 8.14% in Regular Trading, prior clinical progress and cash runway remain in focus","media":"Market Focus","content":"<p><p>On October 19, Veradermics, Inc. rose 8.14% in Regular Trading, trading at $119.375 per share, with turnover of $31.8116 million.</p><p>The latest publicly available company-specific backdrop centers on earlier clinical and financial updates rather than a fresh same-day catalyst. The company previously reported second-quarter EPS of $(0.58), better than the $(0.65) consensus estimate, while net loss widened to $23.5 million from $15.6 million a year earlier but still came in below the expected $26.8 million loss. Veradermics, Inc. also said it held $819.9 million in cash, cash equivalents and marketable securities as of June 30, which it expects will fund operations into 2030 through multiple Phase 3 readouts and a potential commercial launch of VDPHL01.</p><p>Earlier pipeline updates showed VDPHL01 met all primary and key secondary endpoints in a Phase 2/3 male pattern hair loss trial, while a Phase 2 study in female pattern hair loss showed most participants reported improvement after six months with a favorable safety profile. Those developments remain central to how the market is assessing the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Veradermics, Inc. Intraday Rise 8.14% in Regular Trading, prior clinical progress and cash runway remain in focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Veradermics, Inc. Intraday Rise 8.14% in Regular Trading, prior clinical progress and cash runway remain in focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-19 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 19, Veradermics, Inc. rose 8.14% in Regular Trading, trading at $119.375 per share, with turnover of $31.8116 million.</p><p>The latest publicly available company-specific backdrop centers on earlier clinical and financial updates rather than a fresh same-day catalyst. The company previously reported second-quarter EPS of $(0.58), better than the $(0.65) consensus estimate, while net loss widened to $23.5 million from $15.6 million a year earlier but still came in below the expected $26.8 million loss. Veradermics, Inc. also said it held $819.9 million in cash, cash equivalents and marketable securities as of June 30, which it expects will fund operations into 2030 through multiple Phase 3 readouts and a potential commercial launch of VDPHL01.</p><p>Earlier pipeline updates showed VDPHL01 met all primary and key secondary endpoints in a Phase 2/3 male pattern hair loss trial, while a Phase 2 study in female pattern hair loss showed most participants reported improvement after six months with a favorable safety profile. Those developments remain central to how the market is assessing the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MANE","symbol_name":"Veradermics, Inc.","start_time":0,"source_url":"","article_id":"1130777913","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130777913","pubTimestamp":1792417380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 19, Veradermics, Inc. rose 8.14% in Regular Trading, trading at $119.375 per share, with turnover of $31.8116 million.The latest publicly available company-specific backdrop centers on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MANE":"Veradermics, Inc."},"translate_title":"走势警报|Veradermics, Inc. 常规交易盘中上涨 8.14%，先前临床进展和现金跑道仍是焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MANE":1},"content_text":"On October 19, Veradermics, Inc. rose 8.14% in Regular Trading, trading at $119.375 per share, with turnover of $31.8116 million.The latest publicly available company-specific backdrop centers on earlier clinical and financial updates rather than a fresh same-day catalyst. The company previously reported second-quarter EPS of $(0.58), better than the $(0.65) consensus estimate, while net loss widened to $23.5 million from $15.6 million a year earlier but still came in below the expected $26.8 million loss. Veradermics, Inc. also said it held $819.9 million in cash, cash equivalents and marketable securities as of June 30, which it expects will fund operations into 2030 through multiple Phase 3 readouts and a potential commercial launch of VDPHL01.Earlier pipeline updates showed VDPHL01 met all primary and key secondary endpoints in a Phase 2/3 male pattern hair loss trial, while a Phase 2 study in female pattern hair loss showed most participants reported improvement after six months with a favorable safety profile. Those developments remain central to how the market is assessing the stock.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130777913","isCrawlerRequest":true}